lmwh

In this episode have a conversation with Dr Michelle Sholzberg on her recent publication from the British Medical Journal entitled Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial (BMJ 2021; 375 doi: https://doi.org/10.1136/bmj.n2400) which was co-authored by an international team on behalf of the RAPID trial investigators.

Dr. Sholzberg received her MDCM and residency training in Internal Medicine at McGill University, completed additional postgraduate training in Hematology at the University of Toronto and a research hemostasis fellowship in Toronto and internationally. Dr. Sholzberg has a Master of Science from the University of Toronto in Clinical Epidemiology and Health Care Research and was awarded the Claire Bombardier award for career promise as a scientist. She is a clinician-investigator with a focus on coagulation, the Division Head of Hematology-Oncology and the Medical Director of the Coagulation Laboratory at St. Michael’s Hospital. She is also the Director of the Hematology-Oncology Clinical Research Group and Co-director of the Hematology-Immunology Translational Research Theme of the Li Ka Shing Knowledge Institute. Dr. Sholzberg is the associate editor for illustrated materials at Research and Practice in Thrombosis and Haemostasis. Currently, she is involved in the study of: prediction tools for perioperative and traumatic bleeding, the intersection of women’s health and bleeding disorders, treatments for iron deficiency anemia, new treatments for immune thrombocytopenia and the management of COVID-19 coagulopathy.

Follow us on Twitter:

Dr Michelle Sholzberg: @sholzberg

Thrombosis Canada: @ThrombosisCan

 Reference:

Sholzberg M, Tang GH, Rahhal H, AlHamzah M, Kreuziger LB, Áinle FN, Alomran F, Alayed K, Alsheef M, AlSumait F, Pompilio CE. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ. 2021 Oct 14;375.

https://thrombosiscanada.ca

Take a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

In this episode we are joined by Dr Vicky Tagalakis and Dr Marc Carrier, two of the authors of a recently published review paper entitled Treatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus. The paper was published in Current Oncology (Curr. Oncol. 2021, 28, 5434–5451. https://www.mdpi.com/1718-7729/28/6/453). The authors speak about why this update was undertaken and discuss many of the challenging scenarios encountered with this patient group and the recommendations for managing them. Join us for this insightful discussion that can help you in managing patients with cancer at risk of thrombosis.

Dr. Vicky Tagalakis, is an Associate Professor of Medicine at McGill University and an attending in the Department of Medicine of the Jewish General Hospital. She is Director of the Division of General Internal Medicine at McGill University. She is a Research Scientist in the Centre of Epidemiology and Community of Studies, Lady Davis Institute for Medical Research, Jewish General Hospital. She holds several peer-reviewed grants. She is Co-Lead of the Quality Improvement Platform of CanVECTOR), a CIHR funded national research network on venous thromboembolism (VTE).

Dr. Marc Carrier, is the Head of the Division of Hematology at The Ottawa Hospital, a Professor in the Faculty of Medicine, Department of Medicine and Senior Scientist in the Clinical Epidemiology Program of The Ottawa Hospital Research Institute. He holds a Tier 1 Research Chair in Venous Thromboembolism and Cancer from the Faculty of Medicine at the University of Ottawa. Dr. Carrier is also president of Thrombosis Canada.

Related Thrombosis Canada resources:

Downloadable PDF Algorithm: https://thrombosiscanada.ca/cat-treatment-algorithm-2021/

DOAC Drug-Drug-Interaction tool: Download Here

Thrombosis Canada Cancer-associated Thrombosis (CAT) Clinical Guide: Download Here

Thrombosis Canada Clinical Guides: Visit Here

For other relevant resources, education programs and patient materials visit https://thrombosiscanada.ca

https://thrombosiscanada.ca

Take a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Dr. Eric Ley from Cedars-Sinai Medical Center joins us on Rounds to discuss the recently published Western Trauma Association's Critical Decisions Algorithm for reducing VTE in trauma patients. Early risk stratification, timing and initial dose of LMWH, weight-based dosing, and surveillance screening are just a few of the key topics we discuss on this episode.